EVENITY, (romosozumab -aqqg) injection, 105mg/1.17 mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-880-02.
Published July 30, 2025 · Recall initiated: April 21, 2025
Summary
FDA records drug Class II recall D-0539-2025, published July 30, 2025 and initiated April 21, 2025. Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office; Status: Ongoing; Reported quantity: 2 Pre-filled syringes; Lot: Lot: 1178382, Expiration date: 3/31/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations; potential temperature excursions due to transit delays
What to do
Voluntary: Firm initiated · Letter
Get an email if EVENITY has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- EVENITY
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Distributor
- Within the U.S - OH, VA, FL.
- Lot
- Lot: 1178382, Expiration date: 3/31/2027
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAPROLIA (denosumab), injection, 60mg/mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc.,July 30, 2025
- FDABENLYSTA (belimumab) for injection, 400 mg/20 mL vial, Rx only, NDC 49401-102-01, GSK.July 30, 2025
- FDAclomiPRAMINE Hydrochloride Capsules USP 25 mg, 100 count bottles, 5801 Pelican Bay Boulevard, Suite 500,July 30, 2025
- FDABudesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, RX Only,July 30, 2025
- FDATropicamide-Proparacaine-Phenylephrine-Ketorolac, Sterile Ophthalmic Solution, 1% 0.5% 2.5% 0.5%, 5mL, 2x5MLJuly 30, 2025
- FDAMiddle East Coast brand Tahini Dip; NET WT: 6 OZ (170g); INGREDIENTS: TAHINI, ORGANIC LEMON JUICE, GARLIC,July 30, 2025
Questions about this recall
Was EVENITY, (romosozumab -aqqg) injection, 105mg/1.17 mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-880-02. recalled?
Yes. FDA published recall D-0539-2025 on July 30, 2025. Reported hazard: CGMP Deviations; potential temperature excursions due to transit delays
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: EVENITY.